GRN163L: Phase I/II data

In an open-label, dose-escalation, U.S. Phase I/II trial, GRN163L was

Read the full 101 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE